Market resilience of orthopaedic hip/knee arthroplasty sales during COVID-19
- PMID: 38386064
- DOI: 10.1007/s00402-024-05228-2
Market resilience of orthopaedic hip/knee arthroplasty sales during COVID-19
Abstract
Introduction: The coronavirus 2019 (COVID-19) pandemic led to a marked decrease in elective surgical volume and orthopaedic device sales. The aim of this paper was to quantify this decrease and the related financial impact on the largest hip/knee arthroplasty companies by: (1) tracking individual hip/knee company valuations; (2) calculating aggregate changes in overall hip/knee arthroplasty market valuations; and (3) quantifying quarterly hip/knee revenues relative to prior years.
Materials and methods: Financial data on the top five hip/knee arthroplasty companies by size between January 1, 2019, and October 1, 2020, was collected from a Wall Street financial database, S&P Capital IQ. Changes in valuation of these companies were compared against benchmark market indices, the S&P500 and Vanguard Healthcare ETF. U.S. hip/knee arthroplasty-specific revenue for Q1 and Q2 of 2019 and 2020 was collected from Securities Exchange Commission 10-Q forms. Quarterly revenue changes were calculated using 1-2Q19 revenues as baselines and aggregate to approximate the overall hip/knee arthroplasty market.
Results: The top five hip/knee companies lost $179.2 billion (32.7% loss) in market value from pre COVID-19 market highs to COVID-19 market lows (March 2020), while S&P500 and Vanguard Healthcare ETF decreased 36.1 and 33.2%, respectively. From market lows to October 2020, arthroplasty companies rallied 38.6% while the S&P500 and Vanguard Healthcare ETF regained 43.5 and 56.4% respectively. Notably, this occurred while aggregate 1Q/2Q20 revenue lagged 7.1/41.8% relative to 2019, with an overall decrease of $1.58B (24.8%).
Conclusions: Similar to the overall market and healthcare sector, the top five hip/knee arthroplasty companies have recovered from their COVID market lows. Our results reveal that the valuations of hip/knee companies remained robust during COVID, even as revenues fell, likely due to strong investor confidence in the industry outlook and the greater overall healthcare system utilization.
Keywords: COVID-19; Company revenue; Economic impact; Hip; Joint; Knee; Market capitalization.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Verma P, Dumka A, Bhardwaj A et al (2021) A statistical analysis of impact of COVID19 on the Global Economy and Stock Index returns. SN Comput Sci 2021(21):2–1. https://doi.org/10.1007/S42979-020-00410-W - DOI
-
- Burlacu A, Crisan-Dabija R, Covic A et al (2020) Pandemic lockdown, healthcare policies and human rights: integrating opposed views on COVID-19 public health mitigation measures. Rev Cardiovasc Med 21:509–516. https://doi.org/10.31083/J.RCM.2020.04.274 - DOI - PubMed
-
- World Health Organization (2023) WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. World Health Organization. https://covid19.who.int/ . Accessed 15 June 2021
-
- Jackson JK, Nelson RM, Sutter KM, Sutherland MD (2021) Global Economic effects of COVID-19. Congr Res Serv
-
- Kaye AD, Okeagu CN, Pham AD et al (2020) Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives. https://doi.org/10.1016/j.bpa.2020.11.009 . Best Pract Res Clin Anaesthesiol
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
